A biotechnology company committed to the discovery and development of improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Despite having a decent cash position the company has decided to defer further development of Maxy-G34 until a partner is found to fund it. Given that this is their only program in clinical development, it's difficult to see where things go from here. I know that Neose's GCSF analogue didn't attract a partner and that stock is trading in pennies.